Deadline: 21-Aug-25
The Pfizer is accepting applications for PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape.
Funding Information
- Individual projects requesting up to $350,000 will be considered. The estimated total available budget related to this RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Multi-supported educational programs encouraged.
Target Audience
- Community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic counselors, and other healthcare professionals involved in the care and treatment of patients with mCRPC.
Eligibility Criteria
- Applicant organizations to this RFP must be based in the United States.
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit in the United States, the requesting organization must be accredited.
For more information, visit Pfizer.